ANAPTYSBIO, INC. Deferred Income
ANAPTYSBIO, INC. (ANAB) had Deferred Income of $3.54 million as of 2025-03-31, per its 10-Q filed 2025-05-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredIncome · last filed 2025-05-05
- 2025-03-31: Deferred Income $3.54M.
- 2024-12-31: Deferred Income $0.00.
| Period end | Deferred Income |
|---|---|
| 2025-03-31 | $3.54M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $0.00 10-Q · filed 2025-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |